TY - JOUR
T1 - Impact of balloon post-dilation on clinical outcomes after transcatheter aortic valve replacement with the self-expanding CoreValve prosthesis
AU - Barbanti, Marco
AU - Petronio, Anna Sonia
AU - Capodanno, Davide
AU - Ettori, Federica
AU - Colombo, Antonio
AU - Bedogni, Francesco
AU - De Marco, Federico
AU - De Carlo, Marco
AU - Fiorina, Claudia
AU - Latib, Azeem
AU - Testa, Luca
AU - Bruschi, Giuseppe
AU - Poli, Arnaldo
AU - Giannini, Cristina
AU - Curello, Salvatore
AU - Maffeo, Diego
AU - Sgroi, Carmelo
AU - Martina, Paola
AU - Gulino, Simona
AU - Patanè, Martina
AU - Ohno, Yohei
AU - Attizzani, Guilherme F.
AU - Immè, Sebastiano
AU - Cannata, Stefano
AU - Gentili, Alessandra
AU - Rossi, Agnese
AU - Tamburino, Corrado
N1 - Publisher Copyright:
© 2014 American College of Cardiology Foundation.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Objectives The aim of this study was to assess the incidence and clinical impact of balloon post-dilation (BPD) after transcatheter aortic valve replacement (TAVR) with the CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota).Background BPD is a widely adopted strategy to reduce the degree of paraprosthetic regurgitation in case of transcatheter heart valve underexpansion. However, controversies still remain regarding its real effectiveness and safety.Methods The ClinicalService (a nation-based data repository and medical care project) dataset was analyzed. All patients were dichotomized according to the need for BPD during the index procedure.Conclusions This large study showed that BPD after TAVR was safe and not associated with increased rates of cerebrovascular events, mortality, myocardial infarction, and aortic root injury.Results Among 1,376 patients, BPD of the transcatheter heart valve was performed in 272 (19.8%). In 37% of cases, it was unsuccessful at reducing the paravalvular regurgitation to mild or less. No case of valve embolization, new intravalvular regurgitation, coronary occlusion, and aortic root injury occurred during BPD. There were no statistically significant differences between the 2 groups in the incidence of in-hospital all-cause and cardiovascular mortality, neurological events, myocardial infarction, bleeding, conversion to open-chest surgery, and the need for a permanent pacemaker. The need for BPD did not emerge as an independent risk factor for all-cause (adjusted hazard ratio [HR]: 1.33, 95% confidence interval [CI]: 0.81 to 2.19, p = 0.264) and cardiovascular (adjusted HR: 1.48, 95% CI: 0.74 to 2.97, p = 0.265) mortality at 1 year after the procedure. In addition, BPD did not predispose to higher odds of neurological events during 12 months after TAVR (HR: 0.92, 95% CI: 0.45 to 1.88, p = 0.815).
AB - Objectives The aim of this study was to assess the incidence and clinical impact of balloon post-dilation (BPD) after transcatheter aortic valve replacement (TAVR) with the CoreValve prosthesis (Medtronic Inc., Minneapolis, Minnesota).Background BPD is a widely adopted strategy to reduce the degree of paraprosthetic regurgitation in case of transcatheter heart valve underexpansion. However, controversies still remain regarding its real effectiveness and safety.Methods The ClinicalService (a nation-based data repository and medical care project) dataset was analyzed. All patients were dichotomized according to the need for BPD during the index procedure.Conclusions This large study showed that BPD after TAVR was safe and not associated with increased rates of cerebrovascular events, mortality, myocardial infarction, and aortic root injury.Results Among 1,376 patients, BPD of the transcatheter heart valve was performed in 272 (19.8%). In 37% of cases, it was unsuccessful at reducing the paravalvular regurgitation to mild or less. No case of valve embolization, new intravalvular regurgitation, coronary occlusion, and aortic root injury occurred during BPD. There were no statistically significant differences between the 2 groups in the incidence of in-hospital all-cause and cardiovascular mortality, neurological events, myocardial infarction, bleeding, conversion to open-chest surgery, and the need for a permanent pacemaker. The need for BPD did not emerge as an independent risk factor for all-cause (adjusted hazard ratio [HR]: 1.33, 95% confidence interval [CI]: 0.81 to 2.19, p = 0.264) and cardiovascular (adjusted HR: 1.48, 95% CI: 0.74 to 2.97, p = 0.265) mortality at 1 year after the procedure. In addition, BPD did not predispose to higher odds of neurological events during 12 months after TAVR (HR: 0.92, 95% CI: 0.45 to 1.88, p = 0.815).
KW - TAVR
KW - post-dilation
KW - underexpansion
UR - http://www.scopus.com/inward/record.url?scp=84908133958&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908133958&partnerID=8YFLogxK
U2 - 10.1016/j.jcin.2014.03.009
DO - 10.1016/j.jcin.2014.03.009
M3 - Article
C2 - 25234674
AN - SCOPUS:84908133958
SN - 1936-8798
VL - 7
SP - 1014
EP - 1021
JO - JACC: Cardiovascular Interventions
JF - JACC: Cardiovascular Interventions
IS - 9
ER -